These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35849943)

  • 1. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications.
    Icard P; Simula L; Fournel L; Leroy K; Lupo A; Damotte D; Charpentier MC; Durdux C; Loi M; Schussler O; Chassagnon G; Coquerel A; Lincet H; De Pauw V; Alifano M
    Drug Resist Updat; 2022 Jul; 63():100852. PubMed ID: 35849943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?
    Icard P; Simula L; Wu Z; Berzan D; Sogni P; Dohan A; Dautry R; Coquerel A; Lincet H; Loi M; Fuks D
    Drug Resist Updat; 2021 Dec; 59():100790. PubMed ID: 34924279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives.
    Simula L; Alifano M; Icard P
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fructose-1,6-bisphosphate promotes PI3K and glycolysis in T cells?
    Icard P; Alifano M; Donnadieu E; Simula L
    Trends Endocrinol Metab; 2021 Aug; 32(8):540-543. PubMed ID: 34016523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells.
    Zeng C; Wu Q; Wang J; Yao B; Ma L; Yang Z; Li J; Liu B
    Free Radic Biol Med; 2016 Dec; 101():236-248. PubMed ID: 27989748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
    Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
    Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
    Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
    Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
    Elife; 2020 Sep; 9():. PubMed ID: 32897190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and PI3K/AKT in non-small-cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacogenomics; 2015 Nov; 16(16):1843-62. PubMed ID: 26555006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
    Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
    Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
    Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.